Results 51 to 60 of about 765,112 (149)

Complex karyotype and non‐BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
This graphical abstract illustrates the genetic status in chronic lymphocytic leukaemia (CLL) patients with or without progression on Bruton tyrosine kinase (BTK) inhibitors. It highlights universal clonal evolution, where 100% of progressive disease cases acquired BTK or TP53 mutations.
Kiyomi Mashima   +20 more
wiley   +1 more source

A role for Syk-kinase in the control of the binding cycle of the β2 integrins (CD11/CD18) in human polymorphonuclear neutrophils [PDF]

open access: yes, 2003
A fine control of β2 integrin (CD11/CD18)-mediated firm adhesion of human neutrophils to the endothelial cell monolayer is required to allow ordered emigration.
Walzog, Barbara   +9 more
core   +1 more source

CD20 antigen loss post‐venetoclax/anti‐CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

open access: yesBritish Journal of Haematology, EarlyView.
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the ...
Tamasine Stewart   +15 more
wiley   +1 more source

Bruton’s Tyrosine Kinase Inhibitors: Recent Updates

open access: yes
Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the landscape for the treatment of hematological malignancies, solid tumors, and, recently, autoimmune disorders.
Carlos Silva Rondon   +5 more
core   +1 more source

X-linked agammaglobulinemia - first case with bruton tyrosine kinase mutation from Pakistan [PDF]

open access: yes, 2017
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency with more than 600 mutations in Bruton tyrosine kinase (Bkt) gene which are responsible for early-onset agammaglobulinemia and repeated infections.
Zaidi, Samreen Kulsom   +2 more
core  

Evolution of breast cancer therapeutics: Breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy [PDF]

open access: yes, 2014
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). © 2014 Baishideng Publishing Group Inc.There have been significant improvements in the detection
Hussain, HA, Harvey, A
core   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

open access: yesBritish Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß   +3 more
wiley   +1 more source

Treatment patterns and outcomes among patients treated with second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia

open access: yes
Next-generation Bruton tyrosine kinase inhibitors (BTKis) are standards of care for chronic lymphocytic leukemia (CLL). This study evaluated demographic and clinical characteristics, real-world treatment patterns, and outcomes among patients treated with
Qianhong Fu   +7 more
core   +1 more source

ANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library [PDF]

open access: yes, 2017
Bruton's Tyrosine Kinase (BTK) is a cytoplasmic protein tyrosine kinase with a fundamental role in B-lymphocyte development and activation. The nucleocytoplasmic shuttling of BTK is specifically modulated by the Ankyrin Repeat Domain 54 (ANKRD54) protein
Hyunseok Choi   +39 more
core   +2 more sources

Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE)

open access: yesJournal of International Medical Research
Objective Bruton tyrosine kinase inhibitors and B-cell lymphoma 2 inhibitors are currently the new standard active agents in chronic lymphocytic leukaemia. This observational study describes the real-world use of frontline treatment in Bulgarian patients
Vasko Graklanov   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy